GLP1R and type 2 diabetes mellitus: The ongoing SURPASS-CVOT trial (NCT04255433) is anticipated to yield conclusive answers regarding tirzepatide’s effect on major cardiovascular events when compared to dulaglutide, a long-acting GLP-1 RA that has demonstrated cardioprotective properties in people with T2D who are at high cardiovascular risk [40].